Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of galantamine modulation of circadian rhythm in moderate Alzheimer's disease
2009-013689-18Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Day/night ratio before and after galantamine treatment. Started Mar 2010; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-013689-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013689-18.